Vertex’s Anti-Pain Drug Shows Promising Phase 2 Data Results

Vertex Pharmaceuticals has released promising results from a phase 2 study of its investigational NaV1.8 inhibitor drug, VX-548, in patients experiencing acute pain following abdominoplasty or bunionectomy surgery.

The VX-548 treatment was compared to the opioid hydrocodone bitartrate /acetaminophen treatment option, which is branded as AbbVie’s Vicodin.

In both the abdominoplasty and bunionectomy groups, those treated with VX-548 showed statistically significant improvements in their pain levels over 48 hours.

Vertex Pharmaceuticals said it will discuss the positive study results with regulators and take further steps to develop the drug.